It is known best as the Commission's in-house source of scientific advice. But the JRC’s capabilities go well beyond the theory, not just in helping with oversight of EU regulations, but also in providing much-needed practical help in responding to major humanitarian crises
I don’t want to hear again that an SME is not interested in EU support because there is too much red tape, Commissioner for Regional Policy Corina Creţu says, promising reform
The BEAM Alliance – Biotechs from Europe innovating in Antimicrobial Resistance - brings together 37 companies from ten countries to accelerate progress in dealing with drug-resistant infections
Europe’s pharma industry says the €2.2B cut to Horizon 2020 is misguided, while scientists and MEPs declare themselves happy, for the most part, that the cut is less than the €2.7B originally proposed
A complete ban on animal research would be premature and risk chasing biomedical research out of Europe the Commission says in response to the ‘Stop Vivisection’ European Citizen’s Initiative
Following pressure from the EU Ombudsman, the Commission has responded with a list of changes to the way it recruits experts who advise on legislation. But there is nothing to ensure overall balance, NGOs say
There are several barriers holding back science-industry collaboration, but the most urgent one is the reluctance to protect intellectual property in advance of publishing research results, according to two of Poland’s leading patent attorneys
Since its 2014 launch the SME instrument has attracted applications from across Europe. But the quality is low, with only 12% passing the quality threshold. Bernd Reichert, head of unit at the Executive Agency for SMEs, offers tips for success
Following tough negotiations, the European Commission has announced it will cut €500M less from the Horizon 2020 research programme, after additional money is found in the EU budget
After all the promises about lower fees, small companies are in danger of being priced out of Europe’s new patent regime, complains Eurochambres in a letter to the EU industry chief
Shortcomings in the framework for clinical trials, little knowledge of intellectual property law and an awkward relationship between scientists and technology transfer offices are holding back science-industry collaboration, but work is in hand to change things
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.